Ivan Ahel Elected as a Fellow of the Academy of Medical Sciences
Ivan Ahel works on ADP-ribosylation, a post-translational modification synthesised by the poly(ADP-ribose) polymerase (PARP) family of enzymes. Through the modification of a variety of mediator/effector proteins, PARPs control cellular processes that are critical for genome stability, including DNA repair, regulation of chromatin structure, transcription, apoptosis, mitosis and nucleic acid immunity. They have therefore been implicated in a plethora of human diseases, including cancer, neurodegenerative and autoimmune disorders.
Ivan Ahel is the E.P.A. Professor of Chemical Pathology. He is a member of EMBO and was awarded the Biochemical Society GlaxoSmithKline Award in 2022.
Professor Ahel is one of 58 exceptional biomedical and health scientists elected to the Academy this year. The new Fellows have been recognised for their remarkable contributions to advancing biomedical and health sciences, ground-breaking research discoveries and translating developments into benefits for patients and wider society.
The new Fellows will be formally admitted to the Academy at a ceremony on Wednesday 18 September 2024.
Explore more
Ivan Ahel’s group
The group of Ivan Ahel works on the pathways and protein functions underlying genome stability, and in particular the role of the post-translational protein modification ADP-ribosylation in this process.
Cancer and Genome Stability
Several Dunn School groups study processes that are critical to maintain genome integrity and normal cell growth
More news
The latest news stories and research highlights from the Dunn School.